Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum

Developmental Neuroscience

Volumn 20, Issue 2-3, 1998, Pages 146-153

  Poeggeler, Burkhard ^a   Rassoulpour, Arash ^a   Guidetti, Paolo ^a   Wu, Hui Qiu ^a   Schwarcz, Robert ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Amphetamine; D1 receptor; D2 receptor; Excitotoxicity; Kynurenines; Neurodegeneration

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; MALE; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

AGING; ANIMALS; ANIMALS, NEWBORN; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID AGONISTS; HALOPERIDOL; INJECTIONS; KYNURENIC ACID; LIGANDS; MALE; N-METHYLASPARTATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 0031856030     PISSN: 03785866     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017309     Document Type: Article

References (64)

1. Ariano MA, Larson ER, Noblett KL, Sibley DR, Levine MS (1997): Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse 26:400-414.
2. Bal A, Bachelot T, Savasta M, Manier M, Verna JM, Benabid AL, Feuerstein C (1994): Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: In situ hybridation and polymerase chain reaction studies. Mol Brain Res 23:204-212.
3. Bliss TVP, Collingridge GL (1993): A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 361:31-39.
4. Carlsson M, Carlsson A (1990): Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
5. Ceresoli-Borroni G, Schwarcz R (1997): Kynurenines in the prenatal and postnatal rat brain. Soc Neurosci Abstr 23:903.5.
6. Ceresoli G, Fuller MS, Schwarcz R (1996): Excitotoxic lesions of the rat striatum: Different responses of kynurenine pathway enzymes during ontogeny. Dev Brain Res 92:61-69.
7. Chapman AG, Durmuller N, Lees GJ, Meldrum BS (1989): Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibres. Neurosci Lett 107:256-260.
8. Contreras O, Hernandez L (1996): Amphetamine induced dopamine overflow is greater in neonatal than adult rats. Soc Neurosci Abstr 22: 221.18.
9. Dugan LL, Sensi SL, Canzoniero LMT, Handran SD, Rothman SM, Lin T-S, Goldberg MP, Choi DW (1995): Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 15:6377-6388.
10. Filloux F, Wamsley JK (1991): Dopaminergic modulation of excitotoxicity in rat striatum: Evidence from nigrostriatal lesions. Synapse 8: 281-288.
11. Flood JF, Morley JE, Lanthorn TH (1992): Effect of memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol 221:249-254.
12. Foster AC, Vezzani A, French ED, Schwarcz R (1984): Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 48:273-278.
13. Fuller RW, Hambrick-Luecke SK, Ornstein PL (1992): Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist. Neuropharmacology 31:1027-1032.
14. Garofalo P, Colombo S, Lanza M, Revel L, Makovec F (1996): CF 2249: A new putative memory enhancer. Behavioural studies on learning and memory. J Pharm Pharmacol 48:1290-1297.
15. Garside G, Furtado JCS, Mazurek MF (1996): Dopamine-glutamate interactions in the striatum: Behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms. Neuroscience 75:1065-1074.
16. Gerfen CR (1992): The neostriatal mosaic: Multiple levels of compartmental organization. Trends Neurosci 15:133-139.
17. Gerfen CR, Keefe KA, Bloch B, Le Moine C, Surmeier DJ, Reiner A, Levine MS, Ariano MA (1994): Neostriatal dopamine receptors. Trends Neurosci 17:2-5.
18. Germano IM, Pitts LH, Meldrum BS, Bartowski HM, Simon RP (1987): Kynurenate inhibition of cell excitation decreases stroke size and deficits. Ann Neurol 22:730-734.
19. Gill R, Woodruff GN (1990): The neuroprotective actions of kynurenic acid and MK-801 are synergistic and not related to hypothermia. Eur J Pharmacol 176:143-149.
20. Globus MY-T, Ginsberg MD, Dietrich WD, Busto R, Scheinberg P (1987): Substantia nigra lesion protects against ischemic damage in the striatum. Neurosci Lett 80:251-256.
21. Gramsbergen JBP, Hodgkins PS, Rassoulpour A, Turski WA, Guidetti P, Schwarcz R (1997): Brain-specific modulation of kynurenic acid synthesis in the rat. J Neurochem 69:290-298.
22. Graybiel AM, Aosaki T, Flaherty AW, Kimura M (1994): The basal ganglia and adaptive motor control. Science 265:1826-1831.
23. Greene JG, Greenamyre JT (1995): Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 64:430-436.
24. Guidetti P, Okuno E, Schwarcz R (1997): Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res 50:457-465.
25. Hodgkins PS, Schwarcz R (1998): Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur J Neurosci, in press.
26. Hoyt KR, Reynolds IJ, Hastings TG (1997): Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: Interactions with and differences from glutamate-induced cell death. Exp Neurol 143:269-281.
27. Huang N-K, Wan F-J, Tseng C-J, Tung C-S (1997): Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sci 22:2219-2229.
28. Hu X-T, White FJ (1997): Dopamine enhances glutamate-induced excitation of rat striatal neurons by cooperative activation of D1 and D2 class receptors. Neurosci Lett 224:61-65.
29. Ikonomidou C, Price MT, Mosinger JL, Frierdich G, Labruyere J, Salles KS, Olney JW (1989): Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain. J Neurosci 9:1693-1700.
30. Johnston MV, Silverstein FS (1987): Perinatal anoxia; in: Coyle JT (ed): Animal Models of Dementia: A Synpatic Neurochemical Perspective. New York, Liss, pp 223-251.
31. Kelley AE, Delfs M (1994): Excitatory amino acid receptors mediate the orofacial stereotypy elicited by dopaminergic stimulation of the ventrolateral striatum. Neuroscience 60:85-95.
32. Kessler M, Terramani T, Lynch G, Baudry M (1989): A glycine site associated with N-methyl-D-aspartic acid receptors: Characteristics and identification of a new class of antagonists. J Neurochem 52:1319-1328.
33. Klawans HL, Weiner WJ (1974): The effect of d-amphetamine on choreiform movement disorders. Neurology 24:312-318.
34. Konradi C, Levesque J-C, Hyman SE (1996): Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci 16:4231-4239.
35. Lancelot E, Callebert J, Plotkine M, Boulu RG (1995): Striatal dopamine participates in glutamate-induced hydroxyl radical generation. Neuroreport 6:1033-1036.
36. Levine MS, Li Z, Cepeda C, Cromwell HC, Altemus KL (1996): Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 24:65-78.
37. Lowry OH, Rosebrough NJ, Farr NJ, Randall RJ (1951): Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-273.
38. McDonald JW, Johnston MV (1990): Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 15:41-70.
39. Moroni F, Russi P, Carlà V, Lombardi G (1988): Kynurenic acid is present in the rat brain and its content increases during development and aging process. Neurosci Lett 94:145-150.
40. Nestler EJ (1994): Molecular neurobiology of drug addiction. Neuropsychopharmacology 11:77-87.
41. Olney JW (1990): Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol 30:47-71.
42. Perkins MN, Stone TW (1982): An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 147: 184-187.
43. Pittaluga A, Vaccari D, Raiteri M (1997): The 'kynurenate test', a biochemical assay for putative cognition enhancers. J Pharmacol Exp Ther 283:82-90.
44. Poeggeler B, Rassoulpour A, Wu H-Q, Schwarcz R (1997): Effects of dopaminergic drugs on kynurenic acid levels in the developing rat brain. Soc Neurosci Abstr 23:903.14.
45. Rassoulpour A, Wu H-Q, Poeggeler B, Schwarcz R (1996): D-Amphetamine and reserpine modulate kynurenic acid levels in the rat brain in vivo. Soc Neurosci Abstr 22:39.15.
46. Roberts RC, Du F, McCarthy K, Okuno E, Schwarcz R (1992): Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: A light and electron microscopy study. J Comp Neurol 326:82-90.
47. Robertson GS, Vincent SR, Fibiger HC (1992): D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49:285-296.
48. Sauer D, Weber E, Luond G, DaSilva F, Allegrini PR (1995): The competitive NMDA antagonist CGP 40116 permanently reduces brain damage after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 15:602-610.
49. Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, Cipolloni PB, Kowall NW, Rosen BR, Beal MF (1995): Involvement of free radicals in excitotoxicity in vivo. J Neurochem 64: 2239-2247.
50. Schwarcz R, Du F, Schmidt W, Turski WA, Gramsbergen JBP, Okuno E, Roberts RC (1992): Kynurenic acid: A potential pathogen in brain disorders. Ann NY Acad Sci 648:148-153.
51. Schwarcz R, Foster AC, French ED, Whetsell WO Jr, Köhler C (1984): Excitotoxic models for neurodegenerative diseases. Life Sci 35:19-32.
52. Schwarcz R, Fuxe K, Agnati LF, Hökfelt T, Coyle JT (1979): Rotational behavior in rats with unilateral striatal kainic acid lesions: A behavioral model for studies on intact dopamine receptors. Brain Res 170:485-495.
53. Schwarcz R, Guidetti P, Roberts RC (1996): Quinolinic acid and kynurenic acid. Glia-derived modulators of excitotoxic brain injury; in Aschner M, Kimelberg HK (eds): The Role of Glia in Neurotoxicity. Boca Raton, CRC Press, pp 245-262.
54. Schwarcz R, Poeggeler B, Rassoulpour A, Ceresoli-Borroni G, Hodgkins P (1998): Regulation of kynurenic acid levels in the developing rat brain. Amino Acids 14:243-249.
55. Schwarcz R, Shoulson I (1987): Excitotoxins and Huntington's disease; in Coyle JT (ed): Animal Models of Dementia: A Synaptic Neurochemical Perspective. New York, Liss, pp 39-68.
56. Silverman MS, Tootell RBH (1987): Modified technique for cytochrome oxidase histochemistry: Increased staining intensity and compatibility with 2-deoxyglucose autoradiography. J Neurosci Methods 19:1-10.
57. Speciale C, Wu H-Q, Cini M, Marconi M, Varasi M, Schwarcz R (1996): (R,S)-3,4-Dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 315:263-267.
58. Sukekawa K (1991): A fresh mount method for cytochrome oxidase histochemistry. Biotech Histochem 66:99-101.
59. Surmeier DJ, Bargas J, Hemmings HC Jr, Nairn AC, Greengard P (1995): Modulation of calcium currents by a D1 dopaminergic protein kinase phosphatase cascade in rat neostriatal neurons. Neuron 14:385-397.
60. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R (1988): Identification and quantification of kynurenic acid in human brain tissue. Brain Res 454:164-169.
61. Wan FI, Huang NK, Tsong CJ, Tung CS (1997): Multiple mechanisms of amphetamine-induced striatal dopamine depletion in rats. Soc Neurosci Abstr 23:428.5.
62. Wu H-Q, Baran H, Ungerstedt U, Schwarcz R (1992): Kynurenic acid in the quinolinate-lesioned rat hippocampus: Studies in vitro and in vivo. Eur J Neurosci 4:1264-1270.
63. Yamamoto H, Yamamoto T, Goji K, Yang X, Kawai N, Baba A, Moroji T (1996): Non-aminergic effects of amphetamine on the NMDA receptor in primary cultured cortical cells. Ann NY Acad Sci 801:327-339.
64. Zouakia A, Guilloteau D, Zimmer L, Besnard J-C, Chalton S (1997): Evolution of dopamine receptors in the rat after neonatal hypoxia-ischemia: Autoradiographic studies. Life Sci 60: 151-162.